HIV inhibits endothelial reverse cholesterol transport through impacting subcellular Caveolin-1 trafficking
© Lin et al. 2015
Received: 4 March 2015
Accepted: 6 July 2015
Published: 15 July 2015
Human immunodeficiency virus (HIV) infection leads to decreased reverse cholesterol transport (RCT) in macrophages, and Nef mediated down-regulation and redistribution of ATP-binding cassette transporter A1 (ABCA1) are identified as key factors for this effect. This may partially explain the increased risk of atherosclerosis in HIV infected individuals. Since endothelial dysfunction is key in the initial stages of atherosclerosis, we sought to determine whether RCT was affected in human aortic endothelial cells (HAECs).
We found that apoA-I does not significantly stimulate cholesterol efflux in HAECs while cholesterol efflux to high-density lipoprotein (HDL) was dramatically reduced in HAECs co-cultured with HIV infected cells. Studies with wild type and Nef defective HIV revealed no significant differences suggesting that multiple factors are working perhaps in concert with Nef to affect cholesterol efflux to HDL from HAECs. Interestingly, treating HAECs with recombinant Nef showed similar effect in HDL mediated cholesterol efflux as observed in HAECs co-cultured with HIV infected cells. Using a detergent-free based subcellular fractionation approach, we demonstrated that exposure of HAECs to HIV infected cells or Nef alone disrupts caveolin 1 (Cav-1) subcellular trafficking upon HDL stimulation. Moreover, Nef significantly enhanced tyrosine 14 phosphorylation of Cav-1 which may have an impact on recycling of Cav-1 and caveolae.
These results suggest that HIV interferes with cholesterol efflux by HDL in HAECs through the disruption of Cav-1s’ cellular distribution and that multiple factors are involved, possibly including Nef, for the inhibition of HDL mediated cholesterol efflux and alteration of cellular distribution of Cav-1.
Human immunodeficiency virus (HIV) infection is associated with high cardiac risks. An accumulating body of evidence suggests that HIV infection leads to accelerated atherosclerosis [1, 2]. Macrophages, smooth muscle cells (SMCs) and vascular endothelial cells are prominent cell types involved in the progression of atherosclerosis. Key features for atherosclerosis include the accumulation of cholesterol in macrophages and SMCs leading to foam cell formation, and vascular endothelial cell dysfunction, which is considered an early marker for atherosclerosis [3–5]. HIV has been shown to infect human arterial SMCs, and HIV p24 protein has been detected in SMCs from tissue sections of human atherosclerotic plaques obtained from HIV-infected individuals . HIV infection can change endothelial cell function as well as the microenvironment that influences endothelium function [7–9]. Studies in both animal and in vitro models reveal a correlation of endothelial cell dysfunction with HIV envelope gp120, Nef, Tat, and matrix p17 [10–14]. These changes include enhanced expression of cell adhesion molecules, increased permeability of endothelial cells, stimulation of cytokine secretion, endothelial cell proliferation, and apoptosis [10–14]. Furthermore, HIV infection leads to impaired ATP-binding cassette transporter A1 (ABCA1)-dependent cholesterol efflux from human macrophages, which is mediated by Nef induced post-transcriptional down-regulation as well as redistribution of ABCA1 . HIV positive foam cells are present in atherosclerotic plaques of HIV infected patients . Nef treated mice have significantly increased amounts of lipid laden macrophages . These results suggest that direct infection of human macrophages and arterial SMCs by HIV, as well as HIV induced endothelial cell dysfunction are involved in a potential mechanism in a multifactorial paradigm to explain atherosclerosis progression during HIV infection.
Reverse cholesterol transport (RCT) and cholesterol efflux is a pathway to transport accumulated cholesterol from vessel walls to the liver for excretion. By reducing cholesterol from vessel walls, RCT may affect atherosclerosis progression. High-density lipoprotein (HDL) is the main acceptor for cholesterol efflux from cells and considered a protector against atherosclerosis because of its role in RCT [17, 18]. There is substantial information on the influence of HIV infection on macrophage RCT, while the impact on endothelial cell RCT as well as the potential effects on endothelial cell function during HIV infection is not clearly known.
Caveolin-1 (Cav-1), an integral membrane protein of 21- to 24-kDa size, is a major structural component of caveolae and it binds to cholesterol . This molecule was first identified as a major tyrosine-phosphorylated substrate of v-src  and is involved in multiple cellular functions including signal transduction, cholesterol trafficking and efflux, and endocytosis and transcytosis processes [21, 22]. Cav-1 is particularly abundant in endothelial cells and is crucial for the function of these cells. In endothelial cells, Cav-1 and caveolae may play a proatherogenic role. Cav-1 and caveolae promote transcytosis of low-density lipoprotein (LDL)-cholesterol particles from the blood to sub-endothelial spaces . HDL co-localizes with Cav-1 on the cell surface of cholesterol-loaded endothelial cells, and as a consequence, caveolae act as major platforms to facilitate the transport of excess cholesterol to HDL on aortic endothelial cell surfaces .
The relationship between HIV and host factors determines the modulation of various cellular functions and replication of virus within an infected individual. There is limited information on the relationship of HIV infection and Cav-1. Recently, binding of Cav-1 to HIV envelope in the lipid rafts has shown to inhibit cell fusion and subsequently blocks envelope mediated bystander killing [25, 26]. Cav-1 expression is induced significantly in macrophages through a Tat mediated signaling pathway leading to the suppression of HIV replication . In macrophages, Cav-1 overexpression restores Nef mediated impairment of cholesterol efflux to apoA-I . Cav-1 within endothelial cells can act as a proatherogenic protein [29, 30], however, the potential role of Cav-1 in regulating lipid metabolism in endothelial cells and the relative importance of Cav-1 in the regulation of endothelial function under HIV infection is not known. To gain insight into the influence of HIV on lipid metabolism in endothelial cells we evaluated HDL mediated cholesterol efflux and correlated with the dynamic distribution of Cav-1. In addition, we show that recombinant Nef affects the redistribution of Cav-1 in cholesterol loaded endothelial cells upon HDL stimulation perhaps by inducing phosphorylation of Cav-1.
HIV impairs cholesterol efflux by HDL in endothelial cells
The endothelium plays an essential role in cardiovascular health; therefore, endothelial dysfunction is a critical early element in the pathogenesis of atherosclerosis which contributes to plaque initiation and progression [4, 18]. Human aortic endothelial cells (HAECs) also have direct contact with circulating HIV infected cells as well as released viral proteins , and we therefore investigated the influence of HIV infection on endothelial cholesterol homeostasis by monitoring cholesterol efflux in HAECs. We first examined lipid free apoA-I mediated cholesterol efflux in HAECs co-cultured with HIV infected cells. Our results showed that unlike human macrophages apoA-I did not significantly stimulate cholesterol efflux in HAECs (Additional file 1: Figure S1). This may be due to weak expression of ABCA-1 in the HAECs [32, 33]. The inefficient apoA-I mediated cholesterol efflux in HAECs was monitored with cells activated with liver X receptor (LXR) agonist TO-901317 to stimulate ABCA1 expression and cholesterol efflux. Our results showed that after TO-901317 treatment apo-AI did not significantly promote cholesterol efflux (P ˃ 0.05) (Additional file 1: Figure S1). These results correlate with low expression levels of ABCA1 in HAECs and TO-901317 treatment (3 µM) barely elevated endogenous ABCA1 expression in HAECs (Additional file 1: Figure S1) thus confirming that apoA-I does not significantly promote cholesterol efflux in HAECs, which is consistent with Liao et al. previous observations .
Expression levels of Cav-1, ABCA1, ABCG1, and SR-B1 in endothelial cells
Cholesterol trafficking and efflux are regulated by various molecules that include two ATP-binding membrane cassette transport proteins (ABCA1 and ABCG1) cells, scavenger receptor type B class I (SR-BI), and Cav-1 [24, 33]. To reveal the mechanism underlying HIV mediated impairment of cholesterol efflux in endothelial cells we examined the expressions of Cav-1, ABCA1, SR-B1 and ABCG1 in HAECs co-cultured with HIV-infected cells or cultured alone by Western blot analysis. As shown in Figure 1f, the baseline expression of ABCA1 in HAECs is low and there is a slight decrease in ABCA1 when the endothelial cells were co-cultured with HIV-infected cells. In contrast, the abundant expression of Cav-1 is evident. However, the expression levels of Cav-1 remained similar whether endothelial cells were co-cultured with HIV infected cells or not. Moreover, the expression levels of ABCG1 and SR-BI remained the same whether the endothelial cells were co-cultured with infected cells or not. Therefore, the expression levels ABCA1, ABCG1, SR-BI and Cav-1 in HAECs co-cultured with HIV infected cells are not significantly affected.
Cav-1 distribution in endothelial cells co-cultured with HIV infected cells
The potential impact of Nef on cholesterol efflux by HDL in endothelial cells
Nef treatment alters Cav-1 distribution during HDL stimulation
Nef stimulates Cav-1 phosphorylation
Human immunodeficiency virus regulates RCT in macrophages leading to the accumulation of cholesterol in macrophages followed by foam cell transformation, which provides the evidence for HIV related atherosclerotic diseases. However, the alteration of RCT and cholesterol efflux within vascular endothelial cells remains unsolved. Cav-1 is expressed in macrophages, SMCs and vascular endothelial cells, the three prominent cell types which are all involved in atherosclerosis. This molecule, which is particularly enriched in endothelial cells and the most prominent component of endothelial caveolae, is considered a crucial regulator for cholesterol homeostasis in vascular endothelial cells [21, 22, 29, 30, 46]. Endothelial dysfunction is considered an early marker for atherosclerosis and well-established response to cardiovascular risk [4, 5, 18, 47, 48]. In this study, we investigated cholesterol efflux in HAECs co-cultured with HIV-infected cells. Our results showed that cholesterol efflux to HDL is significantly reduced in endothelial cells when co-cultured with HIV-infected cells. There was no significant difference in HDL mediated cholesterol efflux in endothelial cells co-cultured with wild type or Nef defective HIV suggesting multiple factors are involved in HIV induced suppression of HDL mediated cholesterol efflux in HAECs. Furthermore, the reduction is related to impaired Cav-1 redistribution upon HDL stimulation. Interestingly, treatment of HAECs with recombinant Nef revealed a similar effect as HIV infection on cholesterol efflux and Cav-1 redistribution. In addition, Nef induced phosphorylation of Cav-1 at Tyr14 in the endothelial cells, which can influence Cav-1 redistribution. These results show that there is an HIV mediated disruption of cholesterol efflux in endothelial cells, and Cav-1 plays an important role in this process through a change in its trafficking with Nef possibly contributing to these alterations by inducing phosphorylation of Cav-1 Tyr14.
High-density lipoprotein classically functions in the RCT removing cholesterol from peripheral tissues to the bloodstream. Our results show that HIV impairs HDL mediated cholesterol efflux in endothelial cells and that Nef possibly plays a role in this impairment. Interestingly, apoA-I mediated cholesterol efflux was not significant in endothelial cells whether HIV infected cells are present or not, possibly due to low-level endogenous ABCA1 expression. The low level of ABCA1 expression is consistent with studies from others and their results also showed that HDL but not lipid-free apoA-I promotes cellular cholesterol efflux in human umbilical vascular endothelial cells and HAECs under normal conditions [32, 33]. The failure to stimulate ABCA1 dependent cholesterol efflux to apoA-I in endothelial cells in both the presence and absence of HIV shows that ABCA1 is not a major factor in the impairment of RCT from endothelial cells, which is different from previous findings in HIV infected macrophages.
Cav-1 dependent signal transduction and cholesterol trafficking is essential to maintain cellular cholesterol homeostasis. Cav-1 participates in cholesterol trafficking and co-localizes with HDL in cholesterol loaded endothelial cells, indicating caveolae are the major cellular platforms facilitating the transport of excess cholesterol to HDL on the cell surface of aortic endothelial cells [24, 33]. The impact of HIV on the trafficking of Cav-1 as well as HDL mediated cholesterol efflux in endothelial cells would then affect RCT leading to impaired endothelial function. Our results demonstrate HIV or recombinant Nef affects the redistribution of Cav-1 in cholesterol loaded endothelial cells upon HDL stimulation. Nef has been shown to present on surface of infected cells , and is also known to be secreted from infected cells [50–52] and exists in infected patients serum . Nef can be secreted from monocytes and T cells that circulate in the blood stream. This protein is found in the blood stream at significant levels . Furthermore, released Nef is shown to enter into uninfected cells inducing changes in the recipient cells [53–58]. Therefore, Nef can be released from infected cells and enter endothelial cells which then subsequently modulate Cav-1 cellular distribution altering HDL mediated cholesterol efflux. The reason we have not seen a significant difference in HAECs between wild type and Nef defective HIV could be due to a saturation effect on cholesterol efflux by other factors and a higher amount of Nef is needed to demonstrate the impact of Nef on HDL mediated cholesterol efflux. Alternatively, since Nef released from infected cells is associated with exosomes the influence on HDL mediated cholesterol efflux may not be as efficient as using recombinant Nef.
Post-transcriptional modification is important for Cav-1 function in cholesterol homeostasis. It is well documented that Src phosphorylation of Cav-1 is a requirement for activation of the caveolar transport machinery [38–42]. In fact, cholesterol-induced translocation of Cav-1 is modulated by Src activation . In addition, elevated cholesterol stimulates caveolar endocytosis. This process also requires Src kinase and can be modulated by altering the balance of cholesterol and Cav-1 at the plasma membrane . Src kinase induced phosphorylation of Cav-1 dependent signaling is crucial for endothelial function. Cav-1 phosphorylation at Tyr14 is required for integrin-regulated caveolae internalization . Our results, for the first time, shows that Nef induces Cav-1 phosphorylation at Tyr14. This establishes a basis for a link of the association of Nef induced Cav-1 phosphorylation for increased endothelial dysfunction and atherosclerosis in HIV infection derived lipid disorders. Cav-1 phosphorylation is important in caveolae formation and internalization [59, 60]. However, further study is needed to determine whether phosphorylation of Cav-1 at Tyr14 by Nef affects endothelial caveolae dynamics, contributing to changes in Cav-1 distribution upon HDL stimulated cholesterol efflux.
The present studies provide the first evidence for the regulation of endothelial cell RCT by HIV. The intracellular dynamic distribution of Cav-1 in vascular endothelial cells upon HDL stimulation was impacted in the presence of HIV infected cells or recombinant Nef. Induction of phosphorylation of Cav-1 by Nef observed may be a clue to further dissect the molecular mechanisms of these HIV induced changes in endothelial cells. Furthermore, our findings establish that HIV impairs HDL mediated cholesterol efflux in endothelial cells. Recombinant Nef also has a similar effect on HDL mediated cholesterol efflux in endothelial cells. Taken together these data show the role of Cav-1 in the regulation of RCT in HAECs by HIV which can lead to endothelial cell dysfunction and provides a novel candidate to target for modulating HIV infection related atherosclerosis and cardiovascular diseases.
Human aortic endothelial cells (HAECs), originally isolated from human aorta, were purchased from ScienCell Research Laboratories. Recommended endothelial cell culture medium (ECM, ScienCell Research Laboratories, Carlsbad, CA, USA) was used for the culturing of HAECs. HAECs at passages 4–7 were used in all experiments. SupT1, ACH2, A3.01, HUT-78HIV, HUT-78, and U1HIV were kindly provided by the NIH AIDS Research Program. SupT1 cells were cultured in RPMI-1640 containing 10% FBS and penicillin–streptomycin (100 µg/ml). ACH2 is a cloned T-lymphocyte cell derived from A3.01 that are chronically infected with HIV, which consistently produces a low level of virus particles. ACH2 and A3.01 cells were maintained in RPMI 1640 supplemented with 10 mM HEPES, penicillin–streptomycin (100 µg/ml), 2 mM l-glutamine and 10% FBS. HUT-78HIV is a T lymphocyte cell line chronically infected with HIV-1SF2. HUT-78HIV and uninfected HUT-78 cells were grown in RPMI 1640 with penicillin–streptomycin (100 µg/ml) and 10% of FBS. U1HIV is a U937 monocytic cell line infected with HIV, which maintains low constitutive expression of virus. U1HIV and U937 cells were maintained in RPMI 1640 supplemented with penicillin–streptomycin (100 µg/ml), 2 mM l-glutamine and 10% FBS. Co-culture of HAECs with HIV-1-infected cells was performed by adding ACH2, U1HIV, or HUT-78HIV to a monolayer of HAEC in 12 well plates and subsequently incubating for 5 days. ACH2 and U1HIV cells were pre-treated with phorbol 12-myristate 13-acetate (PMA, 10−8 M) for 1–2 days to promote HIV replication. PMA stimulated and un-stimulated ACH2 or U1HIV were co-cultured with HAECs. Controls consisted of HAECs cultured alone or co-cultured with HIV-free parental cells A3.01, U937 and HUT-78. For subcellular fractionation, HIV-infected cells were added to HAECs at 60–70% confluency in 100-mm culture dishes and incubated for 5 days. HUT-78HIV cells were cultured for 3–4 days allowing virus to reach peak production at which point they were co-cultured with HAECs. The culture medium ratio for HAECs and HIV-infected cells is 1:1. Non-adherent cells were removed and adherent HAECs were checked by microscopy to ensure removal of HIV-infected cells before harvesting. Afterwards, HAECs were cultured in regular ECM (basal medium), or in serum free medium containing 0.1% BSA and cholesterol (40 μg/ml) for 36 h, followed by serum free medium without or with HDL (50 μg/ml) for 1–2 h. Nef treatment was carried out by growing HAECs to 70–80% confluency in 100-mm culture dishes with further incubation of the cells in the presence of recombinant Nef (100 ng/ml) for 72 h.
To determine cholesterol efflux by HDL, HAECs were co-cultured with HIV-infected cells (ACH2, HUT-78HIV, U1HIV) or HIV-free parental cell lines (A3.01, HUT-78, U937) at a ratio of 1:3 for 5 days, respectively. ACH2 and U1HIV were pretreated with PMA (10−8 M) for 48 h before co-culture. HAECs and HUT-78HIV cells were co-cultured at ratio 1:1 or 1:5 for 7 days and at ratio 1:3 for 3 and 7 days. HAECs were also co-cultured with PMA (10−8 M) pre-treated (for 48 h) U1HIV or U937 at ratio of 1:3 and incubated for 7 days. HIV-infected cells were then removed and HAECs were rinsed with serum free medium and labeled with 1 μCi/ml [3H] cholesterol and incubated for 36–48 h. Cells were washed gently and cultured for an additional 18 h in serum free medium in the presence or absence of 50 μg/ml HDL (Biomedical Technologies Inc., Stoughton, MA, USA). HDL or mediated cholesterol efflux was determined as described previously . Cholesterol efflux by HDL was measured as the total percentage of radiolabeled cholesterol appearing in the medium in the presence of HDL after subtraction of values of HDL-free medium as described previously . To determine cholesterol efflux from HAECs by apoA-I, cells were labeled with 1 μCi/ml [3H] cholesterol for 24 h. Cells were treated or not with 3 µM LXR agonist TO-901317 (Sigma) for 18 h. After additional culture for 3, 6 or 24 h in presence or absence of 50 μg/ml apoA-l (Biomedical Technologies Inc., Stoughton, MA, USA), counts per minute (CPM) radioactivity levels in culture medium and cell lysates were measured using liquid scintillation counting. Results are cpm in medium as a percentage of cpm in medium plus cpm in cell lysates.
To determine the effect of Nef on cholesterol efflux in HAECs NL4-3 based Nef-positive (pBR43IeG-nef+) and Nef-negative (pBR43IeG-nef−) constructs were obtained from the NIH AIDS Research Program. Infectious virus were generated by calcium phosphate transfection of 293T cells . SupT1 cells were infected with pBR43IeG-nef+ (HIV WT) or pBR43IeG-nef− (HIV Nef−) at a multiplicity of infection (MOI) of 0.005. Twenty-four hours post infection cells were co-cultured with HAECs at ratio 5:1 and medium ratio 1:1 and incubated further for 5 days. SupT1 cells were removed carefully and cholesterol efflux to HDL in HAECs was measured as described above. In a separate experiment, SupT1 cells were infected with HIV WT or HIV Nef- at an MOI 0.005 for 12 days. The supernatants were then harvested and clarified by 3,000 rpm centrifugation and added to HAECs culture at a medium ratio 1:1. HAEC cultures treated with supernatants from infected cells were further incubated for 5 days and cholesterol efflux to HDL was analyzed. To further explore the effect of Nef on HDL mediated cholesterol efflux in HAECs exogenous Nef was added at concentrations of 20, 50, and 100 ng/ml. Cells were incubated for 3 days and cholesterol efflux by HDL was measured as described above.
Sodium carbonate based isolation of Cav-1 enriched membrane fractions
Human aortic endothelial cells from co-culture with HIV infected cells or Nef treated HAECs were harvested using 2 ml of ice-cold 500 mM sodium bicarbonate (Na2CO3) buffer containing 1 mM sodium orthovanadate (Na3VO4), 1 mM sodium fluoride (NaF), 44 μg/ml phenylmethylsulfonyl fluoride (PMSF), and a protease inhibitor mixture [61, 62]. After a 30-min incubation at 4°C, the cells were homogenized with 20 strokes on ice using a pre-chilled Dounce homogenizer and then sonicated with three 20-s bursts. Equal amounts of protein for each sonicated sample was adjusted to 45% sucrose by adding an equal volume of 90% sucrose in 2-(N-morpholino)ethanesulfonic acid (MES)-buffered saline (MBS) to give a final volume of 4 ml. The sample was placed in a Beckmann ultracentrifuge tube and overlaid with 4 ml of 35% sucrose, followed by an overlay of 4 ml of 5% sucrose, both in MBS containing 250 mM Na2CO3. The sucrose gradient was centrifuged at 39,000 rpm for 19 h at 4°C in a swing out Beckmann SW41 rotor. A total of 12 fractions, 1 ml each, from each gradient were collected from top down. Three hundred microliters of each fraction was precipitated with 10% trichloroacetic acid and washed with acetone. Each fraction was analyzed by SDS-PAGE and the protein of interest was detected.
Determination of cell cholesterol content
Human aortic endothelial cells were incubated in regular ECM culture basal medium or in serum free medium containing cholesterol and 1% fatty acid free BSA for 36 h, and cellular cholesterol content was assayed using the Amplex Red cholesterol Assay Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol.
Human aortic endothelial cells were extracted using lysis buffer [50 mM Tris pH 7.5,100 mM NaCl, 1 mM EDTA, 0.1% (v/v) Triton X-100, 10 mM NaF, 1 mM PMSF, and 1 mM Na3VO4] with a complete protease Inhibitor mixture (Roche Diagnostics, Indianapolis, IN, USA) and subjected to SDS-PAGE followed by Western blot with the appropriate primary antibody overnight at 4°C and horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. For determination of Nef expression, culture medium from HIV-infected cells was harvested and clarified at 3,000 rpm centrifugation. Cell culture supernatants were precipitated with trichloroacetic acid TCA (10%) and pellets were collected at 14,000 rpm centrifugation. Pellets were washed four times with ice-cold acetone and resuspended in 2× SDS loading buffer. Protein bands were detected by an ECL kit [chemiluminescent immunodetection system (Amersham, Piscataway, NJ, USA)]. Antibodies used for immunoblots were mouse anti-Phospho-Caveolin-1(pY14) (BD Biosciences, San Jose, CA, USA), rabbit anti-Caveolin-1 (Cell Signaling Technology Inc. Danvers, MA, USA), anti-Flotillin-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ß-actin protein, anti-ß Tubulin (Sigma, St. Louis, MO, USA), anti-Nef (the NIH AIDS Research Program), mouse monoclonal anti-ABCA1, rabbit SR-B1 antibody, and ABCG1 antibody (Novus Biologicals).
Cav-1 phosphorylation assays
Human aortic endothelial cells were grown to 90% confluency, subsequently washed twice with 1× Hank’s Balanced Salt Solution (HBSS) and replaced with fresh complete growth medium. Cells were then treated with 150 ng/ml Nef and collected at various time periods ranging from 5 to 60 min. Cells were lysed and subjected to Western blotting as described above.
Reactive oxygen species (ROS) measurement
OxiSelect™ In Vitro ROS Assay Kit (Cellbiolabs, San Diego, CA, USA) was used to measure ROS according to the manufacturer’s protocol. Briefly, HAECs were first pretreated with 1 mM 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) a cell permeable probe oxidized to elicit fluorescence by ROS for 60 min at 37°C. Cells were then treated with recombinant Nef at 100 ng/ml for various time points (0–60 min), or co-cultured with HUT78HIV at a 1:5 ratio for 3 h. After Nef treatment or co-culture, the HAECs were washed and lysed and further subjected to fluorescent detection by Synergy™ HT Multi-Detection Microplate Reader (Bio-Tek Instruments, Inc.) at 480 nm/530 nm.
Student’s t-test was applied to analyze the differences between sets of data. All analyses were performed with SPSS 12.0.1 for Windows, and were considered significant at P < 0.05.
SL performed all the experiments and wrote the major portion of the manuscript. PEN assisted in some of the experiments and contributed to the writing of the manuscript. AM contributed to the writing of the manuscript and oversaw the progress of the experiments. All authors read and approved the final manuscript.
This research was supported by a grant from the National Institutes of Health (AI39126) to A.M.
Compliance with ethical guidelines
Competing interests The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G et al (2009) HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 23:589–596PubMedView ArticleGoogle Scholar
- Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M et al (2013) Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS 27:381–389PubMedView ArticleGoogle Scholar
- Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145:341–355PubMed CentralPubMedView ArticleGoogle Scholar
- Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109:III27–III32PubMedView ArticleGoogle Scholar
- Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23:168–175PubMedView ArticleGoogle Scholar
- Eugenin EA, Morgello S, Klotman ME, Mosoian A, Lento PA, Berman JW et al (2008) Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 172:1100–1111PubMed CentralPubMedView ArticleGoogle Scholar
- Dhawan S, Weeks BS, Soderland C, Schnaper HW, Toro LA, Asthana SP et al (1995) HIV-1 infection alters monocyte interactions with human microvascular endothelial cells. J Immunol 154:422–432PubMedGoogle Scholar
- Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada KM, Dhawan S (1996) HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 156:1638–1645PubMedGoogle Scholar
- Nottet HS (1999) Interactions between macrophages and brain microvascular endothelial cells: role in pathogenesis of HIV-1 infection and blood–brain barrier function. J Neurovirol 5:659–669PubMedView ArticleGoogle Scholar
- Caccuri F, Giagulli C, Bugatti A, Benetti A, Alessandri G, Ribatti D et al (2012) HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci USA 109:14580–14585PubMed CentralPubMedView ArticleGoogle Scholar
- Duffy P, Wang X, Lin PH, Yao Q, Chen C (2009) HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J Surg Res 156:257–264PubMed CentralPubMedView ArticleGoogle Scholar
- Jiang J, Fu W, Wang X, Lin PH, Yao Q, Chen C (2010) HIV gp120 induces endothelial dysfunction in tumour necrosis factor-alpha-activated porcine and human endothelial cells. Cardiovasc Res 87:366–374PubMed CentralPubMedView ArticleGoogle Scholar
- Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF et al (2006) HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 174:437–445PubMed CentralPubMedView ArticleGoogle Scholar
- Ullrich CK, Groopman JE, Ganju RK (2000) HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 96:1438–1442PubMedGoogle Scholar
- Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N et al (2006) Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 4:e365PubMed CentralPubMedView ArticleGoogle Scholar
- Cui HL, Ditiatkovski M, Kesani R, Bobryshev YV, Liu Y, Geyer M et al (2014) HIV protein Nef causes dyslipidemia and formation of foam cells in mouse models of atherosclerosis. FASEB J 28:2828–2839PubMed CentralPubMedView ArticleGoogle Scholar
- Calabresi L, Gomaraschi M, Simonelli S, Bernini F, Franceschini G (2015) HDL and atherosclerosis: Insights from inherited HDL disorders. Biochim Biophys Acta 1851(1):13–18Google Scholar
- Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS (2002) Pathogenesis of atherosclerosis: a multifactorial process. Exp Clin Cardiol 7:40–53PubMed CentralPubMedGoogle Scholar
- Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG (1992) Caveolin, a protein component of caveolae membrane coats. Cell 68:673–682PubMedView ArticleGoogle Scholar
- Glenney JR Jr (1989) Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 264:20163–20166PubMedGoogle Scholar
- Parton RG, Simons K (2007) The multiple faces of caveolae. Nat Rev Mol Cell Biol 8:185–194PubMedView ArticleGoogle Scholar
- Harris J, Werling D, Hope JC, Taylor G, Howard CJ (2002) Caveolae and caveolin in immune cells: distribution and functions. Trends Immunol 23:158–164PubMedView ArticleGoogle Scholar
- Frank PG, Lisanti MP (2004) Caveolin-1 and caveolae in atherosclerosis: differential roles in fatty streak formation and neointimal hyperplasia. Curr Opin Lipidol 15:523–529PubMedView ArticleGoogle Scholar
- Chao WT, Fan SS, Chen JK, Yang VC (2003) Visualizing caveolin-1 and HDL in cholesterol-loaded aortic endothelial cells. J Lipid Res 44:1094–1099PubMedView ArticleGoogle Scholar
- Huang JH, Lu L, Lu H, Chen X, Jiang S, Chen YH (2007) Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1. J Biol Chem 282:6143–6152PubMedView ArticleGoogle Scholar
- Wang XM, Nadeau PE, Lo YT, Mergia A (2010) Caveolin-1 modulates HIV-1 envelope-induced bystander apoptosis through gp41. J Virol 84:6515–6526PubMed CentralPubMedView ArticleGoogle Scholar
- Lin S, Wang XM, Nadeau PE, Mergia A (2010) HIV infection upregulates caveolin 1 expression to restrict virus production. J Virol 84:9487–9496PubMed CentralPubMedView ArticleGoogle Scholar
- Lin S, Nadeau PE, Wang X, Mergia A (2012) Caveolin-1 reduces HIV-1 infectivity by restoration of HIV Nef mediated impairment of cholesterol efflux by apoA-I. Retrovirology 9:85PubMed CentralPubMedView ArticleGoogle Scholar
- Frank PG, Woodman SE, Park DS, Lisanti MP (2003) Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol 23:1161–1168PubMedView ArticleGoogle Scholar
- Gratton JP, Bernatchez P, Sessa WC (2004) Caveolae and caveolins in the cardiovascular system. Circ Res 94:1408–1417PubMedView ArticleGoogle Scholar
- Andrade AC, Cotter BR (2006) Endothelial function and cardiovascular diseases in HIV infected patient. Braz J Infect Dis 10:139–145PubMedView ArticleGoogle Scholar
- O’Connell BJ, Denis M, Genest J (2004) Cellular physiology of cholesterol efflux in vascular endothelial cells. Circulation 110:2881–2888PubMedView ArticleGoogle Scholar
- Hassan HH, Denis M, Krimbou L, Marcil M, Genest J (2006) Cellular cholesterol homeostasis in vascular endothelial cells. Can J Cardiol 22(Suppl B):35B–40BPubMed CentralPubMedView ArticleGoogle Scholar
- Liao H, Langmann T, Schmitz G, Zhu Y (2002) Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 22:127–132PubMedView ArticleGoogle Scholar
- Shaul PW (2003) Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol 547:21–33PubMed CentralPubMedView ArticleGoogle Scholar
- Feron O, Balligand JL (2006) Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 69:788–797PubMedView ArticleGoogle Scholar
- Bauer PM, Yu J, Chen Y, Hickey R, Bernatchez PN, Looft-Wilson R et al (2005) Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc Natl Acad Sci USA 102:204–209PubMed CentralPubMedView ArticleGoogle Scholar
- Minshall RD, Tiruppathi C, Vogel SM, Niles WD, Gilchrist A, Hamm HE et al (2000) Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J Cell Biol 150:1057–1070PubMed CentralPubMedView ArticleGoogle Scholar
- Shajahan AN, Timblin BK, Sandoval R, Tiruppathi C, Malik AB, Minshall RD (2004) Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J Biol Chem 279:20392–20400PubMedView ArticleGoogle Scholar
- Shajahan AN, Tiruppathi C, Smrcka AV, Malik AB, Minshall RD (2004) Gbetagamma activation of Src induces caveolae-mediated endocytosis in endothelial cells. J Biol Chem 279:48055–48062PubMedView ArticleGoogle Scholar
- Sun Y, Hu G, Zhang X, Minshall RD (2009) Phosphorylation of caveolin-1 regulates oxidant-induced pulmonary vascular permeability via paracellular and transcellular pathways. Circ Res 105:676–685 (615 p following 685) PubMed CentralPubMedView ArticleGoogle Scholar
- Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB (1997) Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem 272:25968–25975PubMedView ArticleGoogle Scholar
- Hu G, Vogel SM, Schwartz DE, Malik AB, Minshall RD (2008) Intercellular adhesion molecule-1-dependent neutrophil adhesion to endothelial cells induces caveolae-mediated pulmonary vascular hyperpermeability. Circ Res 102:e120–131PubMed CentralPubMedView ArticleGoogle Scholar
- Le Lay S, Hajduch E, Lindsay MR, Le Liepvre X, Thiele C, Ferre P et al (2006) Cholesterol-induced caveolin targeting to lipid droplets in adipocytes: a role for caveolar endocytosis. Traffic 7:549–561PubMedView ArticleGoogle Scholar
- Sharma DK, Brown JC, Choudhury A, Peterson TE, Holicky E, Marks DL et al (2004) Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol Biol Cell 15:3114–3122PubMed CentralPubMedView ArticleGoogle Scholar
- Sowa G (2012) Caveolae, caveolins, cavins, and endothelial cell function: new insights. Front Physiol 2:120PubMed CentralPubMedView ArticleGoogle Scholar
- Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874PubMedView ArticleGoogle Scholar
- Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143PubMedView ArticleGoogle Scholar
- Fujii Y, Otake K, Fujita Y, Yamamoto N, Nagai Y, Tashiro M et al (1996) Clustered localization of oligomeric Nef protein of human immunodeficiency virus type 1 on the cell surface. FEBS Lett 395:257–261PubMedView ArticleGoogle Scholar
- Huang MB, Jin LL, James CO, Khan M, Powell MD, Bond VC (2004) Characterization of Nef–CXCR4 interactions important for apoptosis induction. J Virol 78:11084–11096PubMed CentralPubMedView ArticleGoogle Scholar
- James CO, Huang MB, Khan M, Garcia-Barrio M, Powell MD, Bond VC (2004) Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 78:3099–3109PubMed CentralPubMedView ArticleGoogle Scholar
- Fujii Y, Otake K, Tashiro M, Adachi A (1996) Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett 393:93–96PubMedView ArticleGoogle Scholar
- Vilhardt F, Plastre O, Sawada M, Suzuki K, Wiznerowicz M, Kiyokawa E et al (2002) The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem 277:42136–42143PubMedView ArticleGoogle Scholar
- Salmen S, Colmenares M, Peterson DL, Reyes E, Rosales JD, Berrueta L (2010) HIV-1 Nef associates with p22-phox, a component of the NADPH oxidase protein complex. Cell Immunol 263:166–171PubMedView ArticleGoogle Scholar
- Olivetta E, Pietraforte D, Schiavoni I, Minetti M, Federico M, Sanchez M (2005) HIV-1 Nef regulates the release of superoxide anions from human macrophages. Biochem J 390:591–602PubMed CentralPubMedView ArticleGoogle Scholar
- Lenassi M, Cagney G, Liao M, Vaupotic T, Bartholomeeusen K, Cheng Y et al (2010) HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 11:110–122PubMed CentralPubMedView ArticleGoogle Scholar
- Raymond AD, Campbell-Sims TC, Khan M, Lang M, Huang MB, Bond VC et al (2011) HIV Type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals. AIDS Res Hum Retrovir 27:167–178PubMed CentralPubMedView ArticleGoogle Scholar
- Muratori C, Cavallin LE, Kratzel K, Tinari A, De Milito A, Fais S et al (2009) Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 6:218–230PubMedView ArticleGoogle Scholar
- del Pozo MA, Balasubramanian N, Alderson NB, Kiosses WB, Grande-Garcia A, Anderson RG et al (2005) Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat Cell Biol 7:901–908PubMed CentralPubMedView ArticleGoogle Scholar
- Orlichenko L, Huang B, Krueger E, McNiven MA (2006) Epithelial growth factor-induced phosphorylation of caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. J Biol Chem 281:4570–4579PubMedView ArticleGoogle Scholar
- Yue L, Mazzone T (2011) Endogenous adipocyte apolipoprotein E is colocalized with caveolin at the adipocyte plasma membrane. J Lipid Res 52:489–498PubMed CentralPubMedView ArticleGoogle Scholar
- Hayashi H, Mizuno T, Michikawa M, Haass C, Yanagisawa K (2000) Amyloid precursor protein in unique cholesterol-rich microdomains different from caveolae-like domains. Biochim Biophys Acta 1483:81–90PubMedView ArticleGoogle Scholar